

**Table S3: Clinical Characteristics by Study or Study Groups**

Study Number	Disease	N	Age Mean (SD), years	Female Number (%)	Black Number (%)	Median Urine Protein (25 <sup>th</sup> , 75 <sup>th</sup> percentile)
<b>A. RAS Blockade v control</b>						
A1	HTN	877	54.6 (10.7)	339 (38.7)	877 (100)	0.12 (0.04, 0.61)
A2	CKD	122	52.4 (11.6)	44.0 (36.1)	74.0 (60.7)	0.23 (0.10, 0.98)
A3	CKD	103	50.6 (12.9)	35.0 (34.0)	1.0 (1.0)	0.50 (0.10, 2.50)
A4	CKD	562	50.9 (12.5)	157 (27.9)	0.0 (0.0)	0.84 (0.13, 2.46)
A5	CKD	55	49.8 (11.7)	28.0 (50.9)	0.0 (0.0)	1.09 (0.44, 2.60)
A6	CKD	106	46.7 (13.2)	38.0 (35.8)	37.0 (34.9)	1.25 (0.26, 3.14)
A7	CKD	67	45.5 (12.8)	34.0 (50.7)	0.0 (0.0)	1.43 (0.75, 2.95)
A8	CKD	98	51.2 (14.1)	47.0 (48.0)	0.0 (0.0)	1.60 (0.60, 3.20)
A9	IgA	109	40.5 (9.5)	30.0 (27.5)	0.0 (0.0)	1.60 (1.05, 2.61)
A10	CKD	224	44.7 (15.4)	113 (50.4)	0.0 (0.0)	1.69 (1.06, 2.24)
A11	IgA	44	31.6 (11.5)	17.0 (38.6)	0.0 (0.0)	1.70 (1.10, 2.40)
A12	Diabetes	409	34.5 (7.6)	191 (46.7)	32.0 (7.8)	1.86 (1.01, 3.84)
A13	Diabetes	1513	60.2 (7.4)	956 (63.2)	230 (15.2)	2.44 (1.19, 5.18)
A14	CKD	322	48.8 (13.6)	249 (77.3)	2.0 (0.6)	2.75 (1.53, 4.34)
A15	Diabetes	1137	58.8 (7.7)	363 (31.9)	139 (12.2)	3.03 (1.76, 5.40)
<b>B. RAS Blockade v CCB</b>						
B1	HTN	653	54.4 (10.9)	255 (39.1)	653 (100)	0.11 (0.04, 0.57)
B16	Diabetes	392	59.0 (8.2)	130 (33.2)	63.0 (16.1)	0.15 (0.07, 0.84)
B17	CKD	121	55.4 (10.9)	47.0 (38.8)	0.0 (0.0)	1.00 (0.42, 2.60)
B15	Diabetes	1129	59.2 (7.5)	400 (35.4)	147 (13.0)	2.91 (1.68, 5.11)
<b>C. Intensive Blood Pressure</b>						
C1	HTN	1094	54.6 (10.7)	425 (38.8)	1094 (100)	0.12 (0.04, 0.58)
C16	Diabetes	392	59.0 (8.2)	130 (33.2)	63.0 (16.1)	0.15 (0.07, 0.84)
C18	CKD	584	52.2 (12.2)	228 (39.0)	53.0 (9.1)	0.20 (0.06, 1.12)
C19	CKD	255	50.8 (12.8)	104 (40.8)	13.0 (5.1)	0.71 (0.17, 2.04)
C20	CKD	330	54.2 (14.9)	82.0 (24.8)	0.0 (0.0)	2.39 (1.51, 3.66)
<b>D. Low protein diet</b>						
D18	CKD	584	52.2 (12.2)	228 (39.0)	53.0 (9.1)	0.20 (0.06, 1.12)
D19	CKD	255	50.8 (12.8)	104 (40.8)	13.0 (5.1)	0.71 (0.17, 2.04)
<b>E. Immunosuppressive Therapy</b>						
E21	IgA	233	41.9 (13.3)	54.0 (23.2)	2.0 (0.9)	1.80 (1.10, 3.31)
E22	Lupus	228	34.6 (11.7)	200 (87.7)	20.0 (8.8)	3.14 (1.91, 6.20)
E23	Membranous	343	47.4 (11.9)	125 (36.5)	0.0 (0.0)	5.50 (4.00, 8.30)

N, number; SD, standard deviation; RAS, renin-angiotensin system; HTN, hypertension; CKD, chronic kidney disease without specified cause; IgA, immunoglobulin A; CCB, calcium channel blocker; BP, blood pressure.

Note: Each study is referred by an alphanumeric code. Each letter refers to treatment comparisons, and each number refers to the individual studies. **A** is RAS (renin angiotensin system) Blockade vs. Control, **B** is RAS Blockade vs. CCB (calcium channel blocker), **C** is Intensive Blood Pressure **D** is Low protein diet, and **E** is Immunosuppressive therapy. For studies with multiple interventions, there will be multiple letter-number codes for that study. For example, AASK which had multiple interventions: RAS Blockage vs. placebo, RAS Blockade vs. CCB, and Blood pressure control. Its study number is 1, but it has three codes to indicate the specific treatment comparison: A1, B1 and C1.